Tirzepatide

Tirzepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, is increasingly prescribed for obesity and glycemic control. Its effects on gastric emptying, appetite regulation, and rapid weig…

Glucagon-like peptide-1 receptor agonists (GLP-1s), including semaglutide and tirzepatide, are rapidly transforming weight management practices and public discourse surrounding bodies, health, and responsibility. Although biomedical outcomes of GLP-1…

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for metabolic disorders. Howeve, their effects on depressive symptoms and psychological well-being remain uncertain. METHODS: We conducted a systematic review and meta-a…

AIMS: To evaluate 6-month weight-loss outcomes, treatment persistence, and safety of low- to moderate-dose tirzepatide in a real-world clinical setting. METHODS: This multicentre retrospective observational study evaluated adults with obesity who ini…

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have recently emerged as a promising therapeutic option for patients to aid in weight loss; however, little is known about the potential psychiatric side effects of these medications. In this repo…

: Tirzepatide is a novel therapeutic option for the management of metabolic disorders which has started to be implemented in routine practice. The study aimed to analyze the effectiveness of tirzepatide use and patient education in the field of healt…

BACKGROUND: Obesity is a heterogeneous chronic disease in which eating behavior phenotypes may influence treatment response. Yet, anti-obesity medication (AOM) selection is still largely guided by anthropometric and metabolic parameters, with limited…

BACKGROUND: Real-world data directly comparing the safety, tolerability, and effectiveness of semaglutide and tirzepatide in patients with obesity remain limited. This nationwide multicenter observational study compared short-term adverse events, tre…

BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists are increasingly used for the management of diabetes and obesity. However, adverse effects beyond gastrointestinal symptoms remain incompletely characterized. CASE SUMMARY: A 73-year-old w…

The effects on hepatic mitochondrial structure, mitophagy, and cellular homeostasis were investigated when treated with Tirzepatide (Tzp), a dual GIP/GLP-1 receptor agonist, in a mouse model combining obesity, type 2 diabetes, and menopause-condition…

BACKGROUND: Cardiovascular-kidney-metabolic (CKM) syndrome represents a progressive disease continuum linking metabolic risk factors with cardiovascular and kidney disease. Patients in early CKM stages (stages 1-2) represent a critical therapeutic wi…

BACKGROUND: Cardiovascular disease (CVD) and chronic kidney disease (CKD) frequently coexist, with obesity and type 2 diabetes (T2D) being major contributors to adverse outcomes. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and tirzepatide ha…

Although glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose co-transporter 2 inhibitors (SGLT2is) have demonstrated protective effects against chronic kidney disease, their impact on acute kidney injury (AKI) remains unclear. AKI…

Over the last decade, significant progress has been made in cardiorenal protection for metabolic diseases such as type 2 diabetes (T2D) and obesity. With an expanding range of pharmacological options and continuously evolving guidelines, glucagon-lik…

BACKGROUND: Compounded versions of tirzepatide are widely available in the U.S. in the form of fixed‑dose combinations of tirzepatide and various analogs of vitamin B12. These combinations are mass marketed in the U.S. and other countries as comparab…

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed metabolic and aesthetic medicine, yet their potential influence on botulinum toxin type A (BoNT-A) pharmacodynamics remains unexplored. Using the AesthetiSIM™ microsimulation plat…